Filament Health Corp. (FLHLF)
| Previous Close | 0.0900 |
| Open | 0.1052 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's Range | 0.0900 - 0.0900 |
| 52 Week Range | 0.0808 - 0.3680 |
| Volume | |
| Avg. Volume | 5,757 |
| Market Cap | 17.363M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0430 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 1.50 |
- CNW Group
FILAMENT HEALTH IS ISSUED SECOND PATENT BY UNITED STATES PATENT AND TRADEMARK OFFICE AND REPORTS Q1 RESULTS
Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical-stage natural psychedelic drug development company, today announced that it has been issued a second patent by the United States Patent and Trademark Office (USPTO) for the extraction and standardization of natural psilocybin and associated psychedelic compounds. The patent describes essential technology for transforming variable psychedelic raw materials into pharmaceutical-grade, standardized dr
- GlobeNewswire
KCSA Psychedelics Virtual Investor Conference Presentations Now Available for On-Demand Viewing
NEW YORK, April 29, 2022 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced that the presentations from the April 27th and 28th KCSA Psychedelics Virtual Investor Conference are now available for on-demand viewing. REGISTER OR LOGIN NOW AT: https://bit.ly/3OGHgD4 The company presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may download investor materials from the company’s resource section. Comp
- CNW Group
FILAMENT HEALTH ANNOUNCES FOURTH PATENT ISSUANCE
Filament Health Corp. (OTCQB:FLHLF) (NEO:FH) (FSE:7QS) ("Filament" or the "Company"), a clinical-stage natural psychedelic drug development company, today announced that it has been issued a fourth patent for the extraction and standardization of natural psilocybin and associated psychedelic compounds. Filament's latest patent was issued by the Canadian Intellectual Property Office (CIPO) and describes essential technology for transforming variable psychedelic raw materials into pharmaceutical-g
